Ventilator-Associated Pneumonia (VAP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032



Ventilator-associated pneumonia (VAP) is pneumonia or infection in lung parenchyma acquired in patients after invasive mechanical ventilation after 48–72 hours. New or progressive infiltrates, systemic disease (fever, altered white blood cell counts), changes in sputum characteristics, and the detection of a causative agent are seen in VAP patients. VAP is the most common ICU-acquired pneumonia among invasive mechanically ventilated patients. VAP is recognized as a significant issue worldwide and a common healthcare-associated infection (HAI) among developing countries associated with mortality, a longer length of stay, and associated cost burden among patients. The VAP rate varies across studies due to differences in diagnostic criteria, ICUs type, patients' characteristics, and also varying causative microorganisms associated with patients' characteristics, length of stay, and antibiotic use in hospitals. Oropharyngeal and gastric colonization, thermal injuries; posttraumatic, postsurgical intervention factors such as emergency intubation, re-intubation, tracheostomy, bronchoscopy, and inserting nasogastric tube; patients' body positioning, level of consciousness, stress ulcer prophylaxis, and medication use, including sedative agents, immunosuppression, and antibiotics.

·       Ventilator-associated pneumonia (VAP) incidence ranges from 2 to 15 cases per 1000 ICU hospitalization cases.

Thelansis’s “Ventilator-Associated Pneumonia (VAP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ventilator-Associated Pneumonia (VAP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Ventilator-Associated Pneumonia (VAP) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Ventilator-Associated Pneumonia (VAP) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Ventilator-Associated Pneumonia (VAP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033